Aurinia Pharmaceuticals (AUPH) Given New $11.00 Price Target at Raymond James

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) had its price objective boosted by investment analysts at Raymond James from $9.00 to $11.00 in a research report issued on Wednesday. The firm currently has an “outperform” rating on the biotechnology company’s stock. Raymond James’ price target indicates a potential upside of 57.59% from the stock’s current price.

Other equities research analysts have also issued reports about the stock. Cantor Fitzgerald reissued a “buy” rating and set a $24.00 target price (up from $18.00) on shares of Aurinia Pharmaceuticals in a research note on Tuesday. BidaskClub lowered shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Friday, January 25th. Zacks Investment Research raised shares of Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.75 target price on the stock in a research note on Wednesday, January 9th. Finally, Royal Bank of Canada increased their target price on shares of Aurinia Pharmaceuticals from $9.00 to $11.00 and gave the stock a “positive” rating in a research note on Wednesday. Two investment analysts have rated the stock with a sell rating, four have given a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Buy” and an average price target of $13.75.

Shares of Aurinia Pharmaceuticals stock traded up $0.56 on Wednesday, reaching $6.98. The company’s stock had a trading volume of 237,563 shares, compared to its average volume of 856,933. The firm has a market cap of $573.02 million, a price-to-earnings ratio of -7.51 and a beta of 1.38. Aurinia Pharmaceuticals has a 52 week low of $5.01 and a 52 week high of $7.85.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last issued its quarterly earnings results on Tuesday, March 19th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.03). Aurinia Pharmaceuticals had a negative return on equity of 36.10% and a negative net margin of 7,280.85%. The business had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.05 million. On average, research analysts expect that Aurinia Pharmaceuticals will post -0.71 earnings per share for the current fiscal year.

Hedge funds have recently added to or reduced their stakes in the business. Creative Planning raised its holdings in Aurinia Pharmaceuticals by 10.2% in the 4th quarter. Creative Planning now owns 167,657 shares of the biotechnology company’s stock valued at $1,143,000 after acquiring an additional 15,457 shares during the last quarter. FMR LLC raised its holdings in Aurinia Pharmaceuticals by 2.1% in the 3rd quarter. FMR LLC now owns 4,680,959 shares of the biotechnology company’s stock valued at $31,082,000 after acquiring an additional 95,650 shares during the last quarter. Franklin Resources Inc. raised its holdings in Aurinia Pharmaceuticals by 6.1% in the 3rd quarter. Franklin Resources Inc. now owns 1,838,500 shares of the biotechnology company’s stock valued at $12,208,000 after acquiring an additional 105,300 shares during the last quarter. Polar Capital LLP increased its holdings in shares of Aurinia Pharmaceuticals by 17.8% during the 4th quarter. Polar Capital LLP now owns 3,312,723 shares of the biotechnology company’s stock worth $22,593,000 after buying an additional 501,207 shares during the last quarter. Finally, Jane Street Group LLC acquired a new stake in shares of Aurinia Pharmaceuticals during the 3rd quarter worth approximately $182,000. Institutional investors own 24.30% of the company’s stock.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of autoimmune diseases in Canada, the United States, China, and Switzerland. The company is developing voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.

Further Reading: Trading Penny Stocks

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.